sofosbuvir/velpatasvir / Generic mfg. - LARVOL DELTA

CLINICAL OUTCOMES AND MORTALITY PREDICTORS IN HEPATITIS B AND C POSITIVE CHRONIC LIVER DISEASE PATIENTS UNDERGOING MAINTENANCE HEMODIALYSIS IN RESOURCE-LIMITED SETTINGS: A PROSPECTIVE COHORT STUDY (ISN-WCN 2026) - "Direct-acting antivirals (glecaprevir/pibrentasvir or sofosbuvir/velpatasvir) were used for HCV; entecavir or tenofovir alafenamide/disoproxil for HBV with renal dosing. Annual HBV vaccination (89.5% seroprotection) and strict segregation reduced incident infections to zero in segregated units.Conclusion Low albumin and cirrhosis predicted mortality in HBV/HCV-positive CLD patients on MHD. Vaccination, segregation, and timely antiviral therapy were safe, feasible, and associated with improved virologic and survival outcomes in resource-limited dialysis settings."

Clinical • Clinical data • Chronic Kidney Disease • Fibrosis • Hepatitis B • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Renal Disease

Efficacy of Sofosbuvir and Velpatasvir in Achieving Sustained Virological Response in Patients with End-Stage Renal Disease Infected with Hepatitis C Virus (APASL 2026) - No abstract available

Clinical • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Nephrology • Renal Disease

Efficacy of sofosbuvir/velpatasvir in patients with hepatitis C virus genotype 3 infection (APASL 2026) - No abstract available

Clinical • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Effectiveness and Follow-up Challenges of Sofosbuvir/Velpatasvir in HCV/HIV Co-infected Patients: A Real-world Experience from a Chinese Cohort (APASL 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Hepatitis C • Human Immunodeficiency Virus • Infectious Disease

From Crisis to Control: Acute HCV-Triggered Acute-on-Chronic Liver Failure With HRS Successfully Stabilized With Early Sofosbuvir–Velpatasvir and Hemoperfusion: A Case Report (APASL 2026) - No abstract available

Case report • Clinical • Hepatitis C • Hepatology • Liver Failure

MANAGEMENT OF PEDIATRIC HCV-INFECTED PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A MULTICENTER RETROSPECTIVE ITALIAN STUDY (EBMT 2026) - "All patients received myeloablative conditioning, including total body irradiation–based regimens (n=13) or busulfan/treosulfan-based regimens (n=3); one patient received thiotepa, fludarabine, and cyclophosphamide. Cyclosporine, ATG, and ATLG were administered in 9, 4, and 6 patients, respectively; ex vivo and in vivo T-cell depletion was performed in 6 and 1 patients.HCV genotypes were 1 (n=7) and 2 (n=8). Five patients received pre-HCT treatment with lamivudine (n=2), ledipasvir/sofosbuvir(n=2), and ribavirin (n=1), while 9 patients were treated after HCT with sofosbuvir (n=2), ledipasvir/sofosbuvir (n=3), glecaprevir/pibrentasvir (n=3), and sofosbuvir/velpatasvir (n=1); three were never treated... Our data suggest that HCT can be safely performed in pediatric patients with active HCV infection, even in the setting of intensive immunosuppression including in vivo and ex vivo T-cell depletion. Pre-transplant HCV viral load and DAAs exposure did not negatively impact..."

Retrospective data • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Langerhans Cell Histiocytosis • Leukemia • Pediatrics • Transplantation • Transplantation Associated Thrombotic Microangiopathy

MANAGEMENT OF PEDIATRIC HCV-INFECTED PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A MULTICENTER RETROSPECTIVE ITALIAN STUDY (EBMT 2026) - "All patients received myeloablative conditioning, including total body irradiation–based regimens (n=13) or busulfan/treosulfan-based regimens (n=3); one patient received thiotepa, fludarabine, and cyclophosphamide. Cyclosporine, ATG, and ATLG were administered in 9, 4, and 6 patients, respectively; ex vivo and in vivo T-cell depletion was performed in 6 and 1 patients.HCV genotypes were 1 (n=7) and 2 (n=8). Five patients received pre-HCT treatment with lamivudine (n=2), ledipasvir/sofosbuvir(n=2), and ribavirin (n=1), while 9 patients were treated after HCT with sofosbuvir (n=2), ledipasvir/sofosbuvir (n=3), glecaprevir/pibrentasvir (n=3), and sofosbuvir/velpatasvir (n=1); three were never treated... Our data suggest that HCT can be safely performed in pediatric patients with active HCV infection, even in the setting of intensive immunosuppression including in vivo and ex vivo T-cell depletion. Pre-transplant HCV viral load and DAAs exposure did not negatively impact..."

Retrospective data • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Langerhans Cell Histiocytosis • Leukemia • Pediatrics • Transplantation • Transplantation Associated Thrombotic Microangiopathy

Influence of antiviral treatment in hepatitis C patients on metabolism and fibrosis process. (PubMed, Front Med (Lausanne)) - "This study evaluated the effects of two direct-acting antiviral (DAA) regimens-Glecaprevir/Pibrentasvir (G/P) and Sofosbuvir/Velpatasvir (S/V)-on metabolic and inflammatory biomarkers in 70 HCV-infected patients with comorbidities including obesity, type 2 diabetes, and hypertension. DAA therapy significantly alters metabolic and inflammatory biomarkers in HCV patients, with regimen- and fibrosis stage-specific effects. S/V may provide broader metabolic benefits in advanced disease, while G/P offers stronger anti-inflammatory responses earlier, supporting personalized treatment approaches."

Journal • Cardiovascular • Diabetes • Fibrosis • Genetic Disorders • Hepatitis C • Hepatocellular Cancer • Hypertension • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Metabolic Disorders • Obesity • Oncology • Solid Tumor • Type 2 Diabetes Mellitus • CCL2 • FABP1 • FGF • FGF19

THINKER-NEXT: A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients (clinicaltrials.gov) - P2 | N=201 | Completed | Sponsor: University of Pennsylvania | Active, not recruiting ➔ Completed

Trial completion • Chronic Kidney Disease • Hepatitis C • Infectious Disease • Inflammation • Nephrology • Renal Disease • Transplantation

Portal Vein Tryptophan Pathway Analysis Reveals Gut-Mediated Inflammatory Pathway Predominance in HCV Infection. (PubMed, Liver Int) - P | "Elevated kynurenine in portal blood suggests upregulation of gut-mediated pro-inflammatory pathways during HCV infection. Integration of multi-omics data from the gut-liver axis highlights the contribution of the tryptophan pathway to inflammatory responses in HCV. However, small sample size, absence of quantitative values for all pathway metabolites, and reliance on correlative rather than causative associations limit mechanistic interpretation. Future studies with larger cohorts and functional analyses are needed to clarify causal mechanisms and evaluate therapeutic potential of targeting the tryptophan pathway."

Biomarker • Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • CXCL10 • CXCL9 • IL6 • TNFA

AT-01B-008: A Phase 3 Trial Comparing Whether BEM/RZR is Similar to SOF/VEL in Patients with Hepatitis C Virus Infection (clinicaltrialsregister.eu) - P2/3 | N=275 | Recruiting | Sponsor: Atea Pharmaceuticals Inc.

New P2/3 trial • Hepatitis C • Infectious Disease • Inflammation • CD4

Predictive Value of Sustained Virologic Response at Week 4 in Patients with Hepatitis C Virus Infection Treated with Sofosbuvir/Velpatasvir. (PubMed, Viruses) - "High concordance between SVR4 and SVR12 was observed in both ASTRAL and the real-world dataset, supporting the use of SVR4 as a predictor of long-term SVR in patients with HCV infection treated with SOF/VEL. Streamlining cure confirmation by shifting SVR determination from week 12 to week 4 post-treatment may reduce patient loss to follow-up."

Journal • Hepatitis C • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Antiviral treatment for chronic viral hepatitis B and C in children in Ostrava (PubMed, Klin Mikrobiol Infekc Lek) - "Antiviral treatment for chronic VHB in children has become a thing of the past thanks to VHB vaccination. However, chronic VHB persists into adulthood after infection in childhood. Currently, chronic VHC dominates in children. After successful treatment with direct-acting antivirals, further follow-up in adulthood is usually unnecessary."

Journal • Retrospective data • Endocrine Disorders • Hepatitis B • Infectious Disease • Inflammation

Evolution of late hepatitis C relapse among patients with previous sustained virological responses: An 18-year prospective study. (PubMed, J Glob Antimicrob Resist) - "During the 18-year follow-up, 0.199% of SVR patients and 0.188% of OCI patients developed late RCI at 1-5 years after the first SVR. In both late RCI patients, 2nd SVR was achieved using sofosbuvir/velpatasvir. Future studies with comprehensive OCI and late RCI assessments are needed to establish the precise relationships of OCI and hepatic events with late RCI."

Journal • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation

STORC: Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy (clinicaltrials.gov) - P4 | N=100 | Recruiting | Sponsor: Catherine Anne Chappell | Trial primary completion date: Dec 2025 ➔ Apr 2026

Trial primary completion date • Hepatitis C • Infectious Disease • Inflammation

Histopathological features and eight-week split-tablet sofosbuvir/velpatasvir treatment in young children with acute hepatitis C: a case-series study. (PubMed, BMC Infect Dis) - No abstract available

Journal • Hepatitis C • Infectious Disease • Inflammation

Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients. (PubMed, Hepatol Res) - "Retreatment with SOF/VEL + RBV, GLE/PIB for 12 weeks, or SOF/LDV achieved high SVR12 rates, indicating that effective viral eradication is feasible using currently available DAA regimens even after prior treatment failure."

Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Community-based integrated care for HIV, viral hepatitis and sexually transmitted infections, Thailand. (PubMed, Bull World Health Organ) - "Eligible participants with HCV infection received a 12-week course of sofosbuvir-velpatasvir...Community-based HCV treatment of people who use drugs in Thailand, within harm reduction settings, is safe and effective. Integration of this strategy into national programmes could enhance HCV elimination in people who use drugs."

Journal • Hepatitis B • Hepatitis C • Human Immunodeficiency Virus • Infectious Disease • Inflammation

TROJAN-C: Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients (clinicaltrials.gov) - P2 | N=15 | Recruiting | Sponsor: Baylor Research Institute | Active, not recruiting ➔ Recruiting | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Enrollment open • Trial completion date • Trial primary completion date • Cardiovascular • Heart Failure • Hepatitis C • Infectious Disease • Inflammation • Transplantation

Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi. (PubMed, J Clin Oncol) - "HCV eradication by DAAs was achieved in 100% of HCV-positive patients with indolent lymphomas not requiring immediate conventional treatment and resulted in non-negligible rate of lymphoma responses. Treatment with DAAs should be considered as the first-line therapy in this setting."

Journal • Hematological Disorders • Hematological Malignancies • Hepatitis C • Hepatology • Indolent Lymphoma • Infectious Disease • Inflammation • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Sofosbuvir/Velpatasvir in Chronic Hepatitis C, Compensated and Decompensated Cirrhosis, and Retreatment Settings. (PubMed, Intern Med) - "Methods This multicenter prospective study enrolled 236 patients treated with SOF/VEL (with ribavirin for retreatment) at 21 Japanese institutions (chronic hepatitis, n=35; compensated cirrhosis, n=43; decompensated cirrhosis, n=134; undergoing DAA retreatment, n=24). Conclusion SOF/VEL has demonstrated high efficacy in all stages of hepatitis C, including patients with chronic hepatitis, compensated cirrhosis, decompensated cirrhosis, and prior DAA failure. The ability to achieve high efficacy at any stage of chronic hepatitis C is expected to improve the prognosis for a wide range of patients."

Journal • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

Effectiveness of Sofosbuvir/Velpatasvir in a Patient with Ultra-Short Bowel Syndrome and Hepatitis C Virus Infection: A Case Report. (PubMed, Gastroenterol Hepatol) - No abstract available

Journal • Gastrointestinal Disorder • Hepatitis C • Infectious Disease • Inflammation • Short Bowel Syndrome

Virological and antifibrotic efficacy of antiviral treatment for hepatitis В+C in HIV-positive patients. (PubMed, Wiad Lek) - " In patients with HIV/HBV/HCV coinfection, interferon-free regimens that include two direct-acting antivirals, either alone or in combination with ribavirin, demonstrated 100 % virologic efficacy and the most beneficial effects on the liver reducing the degree of liver fibrosis."

Journal • Fibrosis • Hepatitis B • Hepatitis C • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

Shortening Hepatitis C Treatment in Correctional Facilities: Impact of Early Viral Response and Ribavirin Use in 8-Week Sofosbuvir/Velpatasvir (SOF/VEL) Regimens (ASHP 2025) - No abstract available

Hepatitis C • Hepatology • Infectious Disease • Inflammation

Hepatitis C Treatment During Pregnancy: Time for a Practice Change. (PubMed, Am J Obstet Gynecol MFM) - "Ledipasvir/sofosbuvir and sofosbuvir/velpatasvir currently have the most data available in pregnancy and should be included in conversations regarding HCV treatment in pregnancy. Multidisciplinary care between maternal-fetal medicine, infectious disease, and hepatology can help promote access to HCV treatment in pregnancy."

Journal • Review • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Obstetrics